Public disclosure of inside information according to article 17 MAR
Leverkusen (pta038/21.11.2022/21:50) - The management board and supervisory board resolved today to submit, among others, a resolution proposal for a capital increase at an extraordinary shareholders' meeting to be convened shortly.
It is to be proposed to resolve on an capital increase to increase the share capital of the Company by up to EUR 7,089,673 by issuing up to 7,089,673 new no-par value registered shares of the Company. Shareholders will be granted subscription rights. The subscription price per new share shall be EUR 1.05.
The proceeds from the capital increase shall be used to pre-finance the costs for the expected increased orders in the manufacturing business.
(end)
emitter: Biofrontera AG
address: Hemmelrather Weg 201, 51377 Leverkusen
country: Germany
contact person: Investor Relations
phone: +49 (0) 214 87 63 20
e-mail: ir@biofrontera.com
website: www.biofrontera.com
ISIN(s): DE0006046113 (share)
stock exchanges: regulated market in Frankfurt, Dusseldorf; free market in Stuttgart, free market in Munich; open market in Berlin, Tradegate